Size does matter: Comparison of activity between anti-EGFR and anti-VEGF based-treatments in RAS wild type colorectal cancer patients, stratified by sizes of metastatic involvement

Size does matter: comparison of activity between anti-EGFR and anti-VEGF based-treatment in RAS wild type colorectal cancer patients, stratified by size of metastatic involvement

Annals of Oncology ◽

10.1093/annonc/mdx422.013 ◽

2017 ◽

Vol 28 ◽

pp. vi7

Author(s):

M. Del Prete ◽

R. Giampieri ◽

A. Bittoni ◽

A. Bruschi ◽

M. Caramanti ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Wild Type ◽

Anti Vegf ◽

Metastatic Involvement ◽

The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild type colorectal cancer patients receiving irinotecan/cetuximab

Annals of Oncology ◽

10.1093/annonc/mdx422.021 ◽

2017 ◽

Vol 28 ◽

pp. vi9-vi10

Author(s):

M. Puzzoni ◽

L. Demurtas ◽

R. Giampieri ◽

P. Ziranu ◽

V. Pusceddu ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Copy Number ◽

Primary Tumour ◽

Gene Copy Number ◽

Gene Copy ◽

Wild Type ◽

Egfr Gene ◽

Abstract 937: Molecular analysis of KRAS exon 2 wild type colorectal cancer patients enrolled in the CAPRI clinical trial reveals high degree of tumor heterogeneity

10.1158/1538-7445.am2014-937 ◽

2014 ◽

Author(s):

Anna Maria Rachiglio ◽

Matilde Lambiase ◽

Francesca Fenizia ◽

Claudia Esposito ◽

Cristin Roma ◽

...

Keyword(s):

Colorectal Cancer ◽

Clinical Trial ◽

Cancer Patients ◽

Molecular Analysis ◽

Tumor Heterogeneity ◽

Wild Type ◽

Exon 2 ◽

Colorectal Cancer Patients ◽

High Degree ◽

Kras Exon

Abstract 2619: Genetic landscape of KRAS-NRAS-BRAF-PIK3CA wild type metastatic colorectal cancer patients enrolled in the CAPRI clinical trial

10.1158/1538-7445.am2018-2619 ◽

2018 ◽

Author(s):

Anna Maria Rachiglio ◽

Matilde Lambiase ◽

Francesca Fenizia ◽

Alessia Iannaccone ◽

Cristin Roma ◽

...

Keyword(s):

Colorectal Cancer ◽

Clinical Trial ◽

Cancer Patients ◽

Wild Type ◽

Genetic Landscape ◽

FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial

Annals of Oncology ◽

10.1093/annonc/mdz155.088 ◽

2019 ◽

Vol 30 ◽

pp. iv23-iv24 ◽

Cited By ~ 3

Author(s):

A. Fernández Montes ◽

N. Martinez Lago ◽

J. De la Cámara Gómez ◽

M. Covela Rúa ◽

A. Cousillas Castiñeiras ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Treatment Phase ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

First Line ◽

A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients

British Journal of Cancer ◽

10.1038/s41416-019-0537-z ◽

2019 ◽

Vol 121 (5) ◽

pp. 378-383 ◽

Author(s):

Elena Elez ◽

Carles Pericay ◽

Manuel Valladares-Ayerbes ◽

Inmaculada Bando ◽

Maria Jose Safont ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Salvage Therapy ◽

Phase 2 ◽

Wild Type ◽

Exon 2 ◽

Phase 2 Study ◽

Colorectal Cancer Patients ◽

Kras Exon

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial

Cancer Communications ◽

10.1186/s40880-019-0374-8 ◽

2019 ◽

Vol 39 (1) ◽

pp. 28 ◽

Author(s):

Yuankai Shi ◽

Jin Li ◽

Jianming Xu ◽

Yan Sun ◽

Liwei Wang ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Open Label ◽

Phase Iii Trial ◽

397O Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study

Annals of Oncology ◽

10.1016/j.annonc.2020.08.508 ◽

2020 ◽

Vol 31 ◽

pp. S409-S410

Author(s):

E. Martinelli ◽

G. Martini ◽

T. Troiani ◽

F. Pietrantonio ◽

A. Avallone ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Wild Type ◽

P-78 Early tumour shrinkage, depth of response and survival outcomes for RAS wild-type metastatic colorectal cancer patients classified by baseline tumour load: Retrospective pooled analysis of panitumumab PRIME/PEAK studies

Annals of Oncology ◽

10.1016/j.annonc.2020.04.160 ◽

2020 ◽

Vol 31 ◽

pp. S114-S115

Author(s):

F. Loupakis ◽

M. Peeters ◽

M. Geissler ◽

D. Modest ◽

M. Valladares-Ayerbes ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Pooled Analysis ◽

Survival Outcomes ◽

Wild Type ◽

Depth Of Response ◽

Tumour Load ◽

Tumour Shrinkage ◽

A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-016-3111-x ◽

2016 ◽

Vol 78 (3) ◽

pp. 567-575 ◽

Author(s):

Naoki Takahashi ◽

Satoru Iwasa ◽

Masaru Fukahori ◽

Kazuki Sudo ◽

Yusuke Sasaki ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase I ◽

Cancer Patients ◽

Phase I Study ◽

Wild Type ◽

Previously Treated ◽